Clinical Review

2020 Update on bone health

Author and Disclosure Information

A bone health expert considers recent evidence on osteosarcopenia as a risk factor, consequences of delayed denosumab dosing, bisphosphonates and atypical femur fracture, and the T-score as a treatment target in a romosozumab study


 

References

Increasingly, bone health and fragility fracture prevention is one of the most important aspects of healthy aging that we, as women’s health care providers (HCPs), must be sure is part of our thought process in caring for women at midlife and beyond. Virtually all ObGyn HCPs are aware of breast health, both in terms of the clinical breast exam and imaging surveillance. The 5-year relative survival rate for “localized breast cancer” is 99%.1 Most recent data on hip fracture, however, indicate that it is associated with a mortality in the first year of 21%!2 We need to be sure that our patients understand this.

Previously, this column provided an update on osteoporosis. In 2016, I asked to change the focus to “Update on bone health” to highlight that simply relying on dual energy x-ray absorptiometry (DXA) testing of bone mass with arbitrary cutoffs for osteoporosis, osteopenia, and normal bone mass is not adequate for improving overall bone health. The addition of the FRAX fracture risk assessment tool, now widely employed, as well as the trabecular bone score (TBS), not widely employed, helps to refine the assessment of patients’ risk status. Further, issues such as sarcopenia, adequate dietary calcium and vitamin D supplementation, and fall prevention (improving balance, use of nonskid rugs in the bathroom, avoiding black ice when present, having nothing to slip on between the bed and the bathroom in the middle of the night, and so on) also are essential elements of “bone health.”

Finally, I cannot stress enough the importance of developing a good relationship with whatever facility one uses for DXA testing in order to maximize use of the reports and potential limitations. In addition, we should identify a metabolic bone specialist for referral of unusual cases or patients who require medications unlikely to be prescribed by us as ObGyns, and develop some familiarity with therapies that may be utilized.

Osteosarcopenia greatly enhances fall and fracture risk

Sepúlveda-Loyola W, Phu S, Bani Hassan E, et al. The joint occurrence of osteoporosis and sarcopenia (osteosarcopenia): definitions and characteristics. J Am Med Dir Assoc. 2020;21:220-225.

Tokeshi S, Eguchi Y, Suzuki M, et al. Relationship between skeletal muscle mass, bone mineral density, and trabecular bone score in osteoporotic vertebral compression fractures. Asian Spine J. 2020 Sep 3. doi: 10.31616/asj.2020.0045.

Kirk B, Zanker J, Duque G. Osteosarcopenia: epidemiology, diagnosis, and treatment—facts and numbers. J Cachexia Sarcopenia Muscle. 2020;11:609-618.

The topic of sarcopenia as defined by the concurrent presence of low muscle mass, physical performance, and strength has been discussed previously in this Update series.3 Now, osteosarcopenia, defined as the concomitant presence of osteoporosis or osteopenia combined with sarcopenia, seems to be an extremely important gauge of fracture risk, especially now as the population’s longevity has increased dramatically. This new syndrome is associated with higher disability and rates of fracture and falls in older people compared with either entity (the bone component or the sarcopenia component) alone.4,5 In fact, in the 2016 ICD-10-CM, sarcopenia was finally recognized as a disease entity.

Severe sarcopenia is known to increase the risk for falls.6 Furthermore, evidence is increasing of cross talk between muscle and bone.4 The diagnostic criteria of osteopenia and osteoporosis are well established; however, absolute criteria for sarcopenia lack an international consensus.

Continue to: Assess for osteopenia/osteoporosis plus sarcopenia to determine those at greatest fracture risk...

Pages

Recommended Reading

Fracture risk prediction: No benefit to repeat BMD testing in postmenopausal women
MDedge ObGyn
SGLT2 inhibitors with metformin look safe for bone
MDedge ObGyn
Atypical fractures with bisphosphonates highest in Asians, study confirms
MDedge ObGyn
CagA-positive H. pylori patients at higher risk of osteoporosis, fracture
MDedge ObGyn
Treat-to-target strategy ‘not ready for primetime’ in osteoporosis
MDedge ObGyn
Longer bisphosphonate use ups AFF risk, but not all is tied to drug
MDedge ObGyn
Biologics may protect psoriasis patients against severe COVID-19
MDedge ObGyn
Treatment sequence with romosozumab influences osteoporosis outcomes
MDedge ObGyn
Osteoporosis underdiagnosed in older men with fracture
MDedge ObGyn
Denosumab favored over alendronate for BMD protection in glucocorticoid-induced osteoporosis
MDedge ObGyn